Tenon Medical (TNON) Projected to Post Quarterly Earnings on Thursday

Tenon Medical (NASDAQ:TNON) is anticipated to release its Q4 2025 results after the market closes on Thursday, March 19th. Analysts expect Tenon Medical to post earnings of ($0.36) per share and revenue of $1.3780 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:30 PM ET.

Tenon Medical Price Performance

Shares of NASDAQ:TNON opened at $0.81 on Thursday. The business’s 50 day moving average price is $0.86 and its 200-day moving average price is $1.06. The firm has a market capitalization of $8.96 million, a PE ratio of -0.46 and a beta of 1.25. Tenon Medical has a 1 year low of $0.64 and a 1 year high of $5.85.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Tenon Medical in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Tenon Medical has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Investors Weigh In On Tenon Medical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in Tenon Medical during the first quarter worth about $29,000. Geode Capital Management LLC grew its stake in shares of Tenon Medical by 34.6% in the 4th quarter. Geode Capital Management LLC now owns 66,640 shares of the company’s stock valued at $63,000 after buying an additional 17,137 shares during the period. Finally, DRW Securities LLC acquired a new stake in shares of Tenon Medical during the 4th quarter worth approximately $98,000. 22.74% of the stock is currently owned by institutional investors and hedge funds.

Tenon Medical Company Profile

Tenon Medical, Inc is a development-stage medical device company focused on the research, development and commercialization of next-generation surgical biologic adhesives and sealants. The company’s proprietary platform is designed to create tissue-compatible adhesives that can serve as alternatives or complements to traditional sutures and staples, with the goal of improving surgical efficiency, reducing postoperative complications and enhancing patient outcomes.

Tenon Medical’s product pipeline centers on protein-based polymer formulations that cross-link in situ to form a flexible, yet durable, bond with native tissue.